DOSE SPARING KETOROLAC FORMULATIONS AND METHODS AND DEVICES FOR USE WITH SAME
The invention provides a unit dosage form of Ketorolac providing for a reduced dosage than typically provided to a subject in need of same, wherein said dosage form of Ketorolac is in a sterile fluid composition formulated for continuous subcutaneous delivery via body-worn infusion pump assembly, and wherein said Ketorolac is present at a concentration of between 40 mg/mL and 240 mg/mL formulated for single use delivery in a volume not to exceed 1-10 mL. Methods of use of same, body-worn infusion pump assemblies containing same and containers containing same for incorporation within a body-worn infusion pump assembly for a dose-sparing formulation comprising Ketorolac are also provided.
1 . A method of providing analgesia, anti-pyretic effects or reducing pain in a subject presenting with a pain condition, comprising the steps of:
administering Ketorolac in a sterile fluid composition at a dosage of between 40 mg/mL and 240 mg/mL to said subject and administering said Ketorolac to said subject via continuous subcutaneous delivery.
2 . A method of reducing administration site irritation, inflammation or a combination thereof in a subject presenting with a pain condition, comprising the steps of:
administering Ketorolac in a sterile fluid composition at a dosage of between 40 mg/mL and 240 mg/mL to said subject and administering said Ketorolac to said subject via continuous subcutaneous delivery.
3 . The method of claim 1 , wherein said Ketorolac is Ketorolac tromethamine.
4 . The method of claim 1 , wherein said method provides for reducing a dosage of Ketorolac over time.
5 . The method of claim 1 , wherein said method provides for sustaining a given dosage of Ketorolac over a prolonged period of time.
6 . The method of claim 5 , wherein adverse effects comprise gastrointestinal bleeding, inhibition of platelet function, renal impairment, or a combination thereof.
7 . The method of claim 1 , wherein said method makes use of a selectively activatable body-worn infusion-pump assembly comprising a sealed prefilled drug-reservoir containing a unit dosage form comprising Ketorolac to administer Ketorolac to said subject.
8 . The method of claim 7 , wherein said Ketorolac is formulated for single use delivery in a volume not to exceed 2-5 mL.
9 . The method of claim 8 , wherein Ketorolac is formulated for single use delivery in a volume not to exceed 3 mL.
10 . The method of claim 8 , wherein Ketorolac is formulated for single use delivery in a volume not to exceed 1 mL.
11 . The method of claim 1 , wherein said sterile fluid composition is ethanol free or sodium chloride free.
12 . The method of claim 1 , wherein said subject is administered Ketorolac over a period of time of more than 5 consecutive days.
13 . A method of providing analgesia, anti-pyretic effects, or reducing pain in a subject in need thereof, comprising administering to said subject is Ketorolac in a sterile fluid composition in a continuous subcutaneous infusion at a rate of about 90 mg per 24 hours over period of 24 to 120 hour.
14 . A method of providing analgesia, anti-pyretic effects, or reducing pain in a subject in need thereof, comprising administering to said subject Ketorolac in a sterile fluid composition at a dosage of about 30 mg subcutaneously in a period not exceeding 1 hour followed by a continuous subcutaneous infusion of 90 mg of Ketorolac over the remaining 24 hours, followed by a continuous subcutaneous infusion of Ketorolac at a rate of 120 mg per 24 hours over an additional period of 24 to 96 hours.
15 . A method of providing analgesia, anti-pyretic effects, or reducing pain in a subject in need thereof, comprising administering to said subject a bolus of Ketorolac in a sterile fluid composition at a dosage of about 30 mg intramuscularly or intravenously followed by a continuous subcutaneous infusion of 90 mg of Ketorolac over the first 24 hours, followed by a continuous subcutaneous infusion of Ketorolac at a rate of 120 mg per 24 hours over a period of 24 to 96 hours.
16 . A drug infusion pump loaded with an amount of Keterolac providing for a reduced dosage than typically provided, wherein said Ketorolac is in a sterile fluid composition and said Ketorolac is present at a concentration of between 40 mg/mL and 240 mg/mL formulated for single use delivery in a volume not to exceed 1-10 mL, wherein the drug infusion pump is programmed to deliver the Keterolac via continuous subcutaneous delivery.
17 . The drug infusion pump of claim 16 wherein the said drug infusion pump is a body-worn infusion pump.
18 . The drug infusion pump of claim 17 wherein the said body-worn infusion pump is a pre-filled and preprogrammed pump.
19 . The drug infusion pump of claim 16 , preprogrammed to administer Ketorolac at a dosage of between about 40-120 mg/day.
20 . (canceled)
21 . (canceled)
22 . A drug infusion pump loaded with an amount of Keterolac providing for a reduced dosage than typically provided, wherein said Ketorolac is in a sterile fluid composition and said Ketorolac is present at a concentration of between 40 mg/mL and 240 mg/mL formulated for single use delivery in a volume not to exceed 1-10 mL, wherein the said drug infusion pump delivers the Keterolac via continuous subcutaneous delivery.
23 . A drug infusion pump of claim 22 that is a pre-filled, pre-programmed pump.
24 . The drug infusion pump of claim 23 , wherein said pre-filled, pre-programmed pump is programmed to deliver Ketorolac at a dosage of between about 40-120 mg/day.
25 . The drug infusion pump form of claim 24 , wherein said sterile fluid composition is ethanol-free.
26 . The drug infusion pump form of claim 25 , wherein said Ketorolac is present at a concentration of between 120 mg/mL and 240 mg/mL.
27 . The drug infusion pump of claim 24 , wherein said composition provides for a maximal volume of infusion which does not exceed 5 mL for single use.
28 . The drug infusion pump of claim 16 , wherein said composition comprises Disodium EDTA dihydrate as a preservative in said dosage form.
29 . The drug infusion pump of claim 16 , wherein said composition is at a pH of about from 7.6 to about 8.0.
30 . The drug infusion pump of claim 16 , wherein said composition provides for a maximal volume of infusion which does not exceed 1 mL for single use.
31 . The drug infusion pump of claim 16 , wherein said Ketorolac is provided to a subject at a rate of less than 4 mL/day.
32 . The drug infusion pump of claim 16 , wherein said Ketorolac is Ketorolac tromethamine.
33 . A unit dosage form of Ketorolac providing for a reduced dosage than typically provided, wherein said dosage form of Ketorolac is in a sterile fluid composition formulated for continuous subcutaneous delivery via pre-filled, pre-programmed pump assembly, and wherein said Ketorolac is present at a concentration of between 40 mg/mL and 240 mg/mL formulated for single use delivery in a volume not to exceed 1-10 mL, wherein the reduced dosage of Ketorolac provides a PK profile with Ketorolac blood levels between predetermined 1M and PO dosing regimens based on simulation results from a MMSPK model at a dosage of less than 120 mg/day that provides effective analgesia, antipyretic effects or reduction of pain.
34 . A unit dosage form of Ketorolac in a sterile fluid composition formulated for continuous subcutaneous delivery via pre-filled, pre-programmed pump assembly, wherein said Ketorolac is present at a concentration of between 40 mg/mL and 240 mg/mL formulated for single use delivery in a volume not to exceed 1-10 mL, wherein said composition is alcohol free, sodium chloride free, or a combination thereof, at a pH of about 7.5-8.5 and stable for a period of at least 12 months at room temperature.
35 . The unit dosage form of claim 33 , wherein said composition contains only a single preservative, which preservative is EDTA.